Skip to content
Bretylium
Bretylol (bretylium) is a small molecule pharmaceutical. Bretylium was first approved as Bretylol on 1982-01-01. It is used to treat ventricular fibrillation and ventricular tachycardia in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bretylium tosylate
Tradename
Company
Number
Date
Products
BRETYLIUM TOSYLATE IN DEXTROSE 5%Abbott BiotherapeuticsN-019005 DISCN1986-04-29
3 products
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINERB. Braun MedicalN-019121 DISCN1986-04-29
3 products
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINERBaxterN-019837 DISCN1989-04-12
2 products
BRETYLOLHospiraN-017954 DISCN1982-01-01
1 products
BRETYLIUM TOSYLATEHospiraN-019030 DISCN1986-04-29
1 products, RLD
BRETYLIUM TOSYLATEHospiraN-019033 DISCN1986-04-29
1 products
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINERHospiraN-019008 DISCN1986-04-29
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ventricular fibrillationEFO_0004287D014693I49.01
ventricular tachycardiaD017180I47.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01B: Antiarrhythmics, class i and iii
C01BD: Antiarrhythmics, class iii
C01BD02: Bretylium tosilate
HCPCS
No data
Clinical
Clinical Trials
151 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Head and neck neoplasmsD00625812317
NeoplasmsD009369C80213
WartsD014860B0711
KeloidD007627EFO_0004212L91.011
CicatrixD002921HP_0100699L90.511
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.921918240
Hodgkin diseaseD006689C812121629
Hiv infectionsD015658EFO_0000764B20425112
Germ cell and embryonal neoplasmsD00937335210
Kaposi sarcomaD012514C463238
TeratomaD013724D28346
Ovarian neoplasmsD010051EFO_0003893C561315
Non-hodgkin lymphomaD008228C85.91113
Large b-cell lymphoma diffuseD016403C83.322
CardiotoxicityD066126EFO_100148222
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinoma of head and neckD00007719522
Central nervous system neoplasmsD016543112
Vascular malformationsD054079112
T-cell lymphoma peripheralD016411C84.911
Plasma cell neoplasmsD05421911
PneumocephalusD011007EFO_100139811
Sex cord-gonadal stromal tumorsD018312EFO_100005211
Sertoli-leydig cell tumorD01831011
Female genital neoplasmsD00583311
Neoadjuvant therapyD02036011
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C25213
Stomach neoplasmsD013274EFO_0003897C1611
Brain neoplasmsD001932EFO_0003833C7111
Skin neoplasmsD012878EFO_0004198C4411
MelanomaD00854511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Second primary neoplasmsD01660911
HemangiomaD006391D18.011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBRETYLIUM
INNbretylium tosilate
Description
Bretylium is a quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. It has a role as an adrenergic antagonist, an anti-arrhythmia drug and an antihypertensive agent.
Classification
Small molecule
Drug classquaternary ammonium derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC[N+](C)(C)Cc1ccccc1Br
Identifiers
PDB
CAS-ID59-41-6
RxCUI19685
ChEMBL IDCHEMBL1199080
ChEBI ID3172
PubChem CID2431
DrugBankDB01158
UNII ID78ZP3YR353 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,202 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8,007 adverse events reported
View more details